Literature DB >> 2981953

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG.

H P Taylor, N J Dimmock.   

Abstract

We have found that bile is a useful source of secretory IgA (scIgA) which can specifically neutralize influenza virus infectivity. Using purified scIgA, we compared the mechanism of neutralization with that mediated by IgA monomers (prepared from scIgA by differential reduction) and IgG. At 4 degrees C, scIgA prevented the attachment of neutralized virus, while neither monomeric IgA nor IgG had any affect on this process or on the subsequent stages of infection by which virion RNA accumulates in nuclei. At 25 and 37 degrees C, scIgA permitted the attachment of approximately half the neutralized virus, but the virus was not internalized. Clearly, the neutralization depends on the character of the antibody used. scIgA may act by steric hindrance (with attachment or penetration, depending on temperature), whereas IgA and IgG neutralize infectivity at a stage subsequent to accumulation of the virus genome in the nucleus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981953      PMCID: PMC2187541          DOI: 10.1084/jem.161.1.198

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

Review 1.  Structure and function of immunoglobulin A.

Authors:  T B Tomasi; H M Grey
Journal:  Prog Allergy       Date:  1972

2.  Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness.

Authors:  J C Perkins; D N Tucker; H L Knopf; R P Wenzel; A Z Kapikian; R M Chanock
Journal:  Am J Epidemiol       Date:  1969-12       Impact factor: 4.897

3.  Protection against enteric bacterial infection by secretory IgA antibodies.

Authors:  E S Fubara; R Freter
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

Review 4.  Secretory immunoglobulins.

Authors:  T B Tomasi; J Bienenstock
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

5.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

6.  Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal.

Authors:  R C Williams; R J Gibbons
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Phylogenetic insight into evolution of mammalian Fc fragment of gamma G globulin using staphylococcal protein A.

Authors:  G Kronvall; U S Seal; J Finstad; R C Williams
Journal:  J Immunol       Date:  1970-01       Impact factor: 5.422

8.  Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus.

Authors:  R G Webster; W G Laver
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

9.  Internal proteins of influenza virus: 35S-methionine peptide maps as genetic markers.

Authors:  N J Dimmock; A S Carver; S I Kennedy; M R Lee; S Luscombe
Journal:  J Gen Virol       Date:  1977-09       Impact factor: 3.891

10.  Identification in a recombinant influenza virus of structural proteins derived from both parents.

Authors:  W G Laver; E D Kilbourne
Journal:  Virology       Date:  1966-11       Impact factor: 3.616

View more
  45 in total

1.  Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.

Authors:  K Robinson; L M Chamberlain; M C Lopez; C M Rush; H Marcotte; R W F Le Page; J M Wells
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 2.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

Review 3.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

Review 4.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases.

Authors:  M Kilian; J Mestecky; M W Russell
Journal:  Microbiol Rev       Date:  1988-06

6.  Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies.

Authors:  J Castilla; I Sola; L Enjuanes
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited.

Authors:  S J Armstrong; N J Dimmock
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 8.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

9.  Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A (S-IgA) antibodies to cell surface protein antigen I/II: reversal by IgA1 protease cleavage.

Authors:  G Hajishengallis; E Nikolova; M W Russell
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.